TP53 mutation in prostate needle biopsies - Comparison with patients follow-up

Anticancer Research

Volumn 27, Issue 6 B, 2007, Pages 4143-4148

  Ecke, Thorsten H ^a   Schlechte, Horst H ^b   Hübsch, Anne ^b   Lenk, Severin V ^b   Schiemenz, Katrin ^b   Rudolph, Birgit D ^b   Miller, Kurt ^b  

^a HELIOS Klinikum Bad Saarow   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Benign; Cancer; Follow up; Mutation; Needle biopsy; Prostate; PSA; TP53

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EXON; FOLLOW UP; GEL ELECTROPHORESIS; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MUTATION RATE; NEEDLE BIOPSY; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; SURVIVAL TIME;

BASE SEQUENCE; BIOPSY, NEEDLE; EXONS; FOLLOW-UP STUDIES; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MOLECULAR SEQUENCE DATA; MUTATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS;

EID: 37549029130     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Soussi T, Dehouche K and Béroud C: p53 Website and analysis of p53 gene mutations in human cancer: Forging a link between epidemiology and carcinogenesis. Human Mut 15: 105-113, 2000.
2. Schlechte HH, Schnorr D, Löning T, Rudolph BD, Pohrt UM and Loening SA: Mutation of the tumor suppressor gene p53 in human prostate and bladder cancers - investigation by temperature gradient gel electrophoresis (TGGE). J Urol 157: 1049-1053, 1997
3. Brooks JD, Bova GS, Ewing CM, Piantadosi S, Carter BS, Robinson JC, Epstein JI and IsaacsWB: An uncertain role of p53 gene alterations in human prostate cancers. Cancer Res 56: 3814-3822, 1996.
4. Grignon DJ, Caplan R, Sakar FH, Lawton CA, Hammond EH, Pilepich MV, Forman JD, Mesic J, Fu KK, Abrams RA, Pajak TF, Shipley WU and Cox JD: p53 Status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst 89: 158-165, 1997.
5. Kuczyk MA, Serth J, Bokemeyer C, Machtens S, Minssen A, Bathke W, Hartmann J and Jonas U: The prognostic value of p53 for long-term and recurrence-free survival following radical prostatectomy. Eur J Cancer 34: 679-686, 1998.
6. Kallakury BVS, Jennings TA, Ross JS, Breese K, Figge HL, Fisher HA and Figge J: Alteration of the p53 locus in benign hyperplastic epithelium associated with high-grade prostatic-adenocarcinoma. Diagn Mol Path 3: 227-232, 1994.
7. Navone NM, Troncoso P, Pisters LL, Goodrow PL, Palmer JL, Nichols WW, von Eschenbach AC and Conti CJ: p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85: 1657-1669, 1993.
8. Navone NM, Labate ME, Troncoso P, Pisters LL, Conti CJ, von Eschenbach AC and Logothetis CJ: p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol 161: 304-308, 1999.
9. Berner A, Geitvik G, Karlsen F, Fosså SD, Nesland JM and Børresen AL: TP53 mutations in prostatic cancer. Analysis of pre- and post-treatment archival formalin-fixed tumor tissue. J Pathol 176(3): 299-308, 1995.
10. Schlechte H, Lenk SV, Löning T, Schnorr D, Rudolph BD. Ditscherlein G and Loening SA: p53 tumour suppressor gene mutations in benign prostatic hyperplasia and prostate cancer. Eur Urol 34: 433-440, 1998.
11. Mostofi FK, Sesterhenn IA and Davis CJ Jr: A pathologist's view of prostatic carcinoma. Cancer 71: 906-932, 1993.
12. Sebo TJ, Bock BJ, Cheville JC, Lohse C, Wollan P and Zincke H: The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. J Urol 163: 174-178, 2000.
13. Chan TY and Epstein JI: Follow-up of atypical prostate needle biopsies suspicious for cancer. Urology 53: 351-355, 1999.
14. Thompson IM, Pauler DK, Goodman PJ, Tangem CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ and Coltman CA Jr: Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter. N Engl J Med 350: 2239-46, 2004.
15. Yu H, Levesque MA, Clark GM and Diamandis EP: Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination. Br J Cancer 81: 490-495, 1999.
16. Bergh J, Norberg T, Sjögren S, Lindgren A and Holmberg L: Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Med 1: 1029-1034, 1995.
17. Børresen AL, Andersen TI, Eyfjord JE, Cornells RS, Thorlacius S, Borg A, Johansson U, Theillet C, Scherneck S, Hartmann S et al: Tp53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromos Cancer 14: 71-75, 1995.
18. Heide I, Thiede C, Sonntag T, de Kant E, Neubauer A, Jonas S, Peter FJ, Neuhaus P, Herrmann R, Huhn D and Rochlitz CF: The status of p53 in the metastatic progression of colorectal cancer. Eur J Cancer 33: 1314-1322, 1997.
19. Ichikawa A, Kinoshita T, Watanabe T, Kato H, Nagai H, Tsushita K, Saito H and Hotta T: Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. New Engl J Med 337: 529-534, 1997.
20. Pollack IF, Hamilton RL, Finkelstein SD, Campbell JW, Martinez AJ, Sherwin RN, Bozik ME and Gollin SM: The relationship between Tp53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res 57: 304-309, 1997.
21. Pich A: Review: p53 expression, proliferation activity and prognosis in cancer. The Cancer J 11: 223-228, 1998.
22. Kucera E, Speiser P, Gnant M, Szabo L, Samonigg H, Hausmaninger H, Mittlböck M, Fridrik M, Seifert M, Kubista E, Reiner A, Zeillinger A and Jakesz R: Prognostic significance of mutations in the p53 gene, particularly in the Zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients. Austrian Breast Cancer Study Group. Eur J Cancer 35: 398-405, 1999.
23. Serafin AM and Bohm L: Influence of p53 and bcl-2 on chemosensitivity in benign and malignant prostatic cell lines. Urol Oncol 23: 123-129, 2005.
24. Wong K-B, DeDecker BS, Freund SM, Proctor MR, Bycroft M and Fersht AR: Hot-spot mutants of p53 core domain evidence characteristic local structural changes. Proc Natl Acad Sci USA 96: 8438-8442, 1999.
25. Barnabas N, Shurafa M, Van Dyke DL, Wolman SR, Clark D and Worsham MJ: Significance of p53 mutations in patients with chronic lymphocytic leukemia. Cancer 91: 285-293, 2001.
26. Montie JE: Current prognostic factors for prostate carcinoma. Cancer 78: 341-344, 1996
27. Diamandis EP, Yousef GM, Luo LY, Magklara A and Obiezu CV: The new human kallikrein gene family: Implications in carcinogenesis. Trend Endocrinol Metab 11: 54-60, 2000.
28. Clements J, Hooper J, Dong Y and Harvey T: The expanded human kallikrein (KLK) gene family. Genomic organisation, tissue specific expression and potential functions. Biol Chem 382: 5-14, 2001.
29. Strohmeyer D, Rössing C, Bauerfeind A, Kaufmann O, Schlechte H, Bartsch G and Loening S: Vascular-endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. The Prostate 45: 216-224, 2000.